Prosecution Insights
Last updated: April 19, 2026
Application No. 17/777,027

IMIDAZOPYRIDINE-BASED ARYLAMINE COMPOUND AND USE THEREOF

Final Rejection §103§112
Filed
May 14, 2022
Examiner
MCDOWELL, BRIAN E
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Guangdong Aglaia Optoelectronic Materials Co. Ltd.
OA Round
2 (Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
2y 4m
To Grant
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allow Rate
818 granted / 1102 resolved
+14.2% vs TC avg
Strong +30% interview lift
Without
With
+30.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
58 currently pending
Career history
1160
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
15.0%
-25.0% vs TC avg
§102
19.5%
-20.5% vs TC avg
§112
47.6%
+7.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1102 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of Claims Claims 2-7, 9, and 11-20 are pending in the instant application. Claims 6, 7, 10, and 15-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. An action on the merits of claims 2-5, 9, and 11-14 is contained herein. The scope of claim 2 has been extended to cover species wherein R1 = phenyl and Ar1,2 is a carbocyclic or heteroaryl ring. Priority Applicant’s submission of the appropriate English translated foreign priority documents, see Remarks, filed 11/6/2025, with respect to the Non-Final Office Action mailed 8/21/2025, has been fully considered. Thus, the instant application receives foreign priority date to said document. Previous Objections/Rejections Any rejections or objections stated of record in the office action mailed on 8/21/2025 that are not explicitly addressed herein below, are hereby withdrawn in light of applicant's arguments and/or amendments filed 11/6/2025. New Objections and Rejections Claim Objections Claim 9 is objected to because the instant claims possess non-elected subject matter. Applicant elected group I without traverse, drawn to compounds of the general formula I. However as stated in the previous office action, the claim embrace species not represented by the originally presented subject matter. For example the species starting at B1 are not symmetrical wherein n = 2: PNG media_image1.png 168 762 media_image1.png Greyscale . Applicants mentioned that these compounds meet the limitation wherein n =1 and Ar2 is arylamine. It is unclear how these species could be interpreted by the latter since arylamino is viewed in the art as (aryl-NH2). Even if trying to construe the latter, the amino groups are further substituted (e.g. -NR2) which is further substituted with heteroaryl which again is not supported the originally presented subject matter. There is no guidance in the specification as to the actual definitions of these groups and the art differs in their language as well. Thus the examiner has to use the most reasonable interpretation where these species are not embraced by the formula I presented initially. Even the following species do not fall within the scope of formula I: PNG media_image2.png 156 594 media_image2.png Greyscale wherein R1 = aryl, Ar1 or B selected from aryl or aryl substituted with heteroaryl which is not supported by the originally presented claim 1. The examiner objects to these species that appear to not be embraced by the originally presented formula I and that all should be removed. Correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 11 and 13 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. In the instant claims, the scope of “X1,X2,X3 and X4” is not incorporated into the formula II and it is unclear what these variables are referring to. Does Applicant intend “X1, etc.”? Thus the scope of the claims are indefinite. Correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), fourth paragraph: Subject to the [fifth paragraph of 35 U.S.C. 112 (pre-AIA )], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 5, 11, and 13-14 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 5 does not limit claim 2 with respect to Ar2 being selected from formula III as written. The latter formula suggests that R1 may be selected from arylene or broader C2-C28 heteroarylene which again is substituted further with the fused imidazolyl ring system; neither of the aforementioned is a possibility since claim 2 does not embrace these limitations. Additionally claims 11 and 13 recite variables “X1,X2,X3 and X4” which are not incorporated into the formula II recited in claim 2. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 2-4 and 11-14 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent 8,853,403. The instant claims may be drawn to the following compound: PNG media_image3.png 246 474 media_image3.png Greyscale wherein for formula II, X1-4 is -CH, R2 = phenyl, R1 = Ar1 = phenyl, and Ar2 = heteroaryl substituted with phenyl. US Patent 8,853,403 teaches the following compound at col. 99, example 3: PNG media_image4.png 252 432 media_image4.png Greyscale wherein for formula II, X1-4 is -CH, R2 = H, R1 = Ar1 = phenyl, and Ar2 = heteroaryl substituted with phenyl. Note that the difference between these compounds stem from an extra phenyl group at variable R2 in the claimed compound. However the patent teaches that the two groups (H and phenyl) are equivalent and interchangeable (see col. 4, li.10-15 for variable R51 wherein group A represents the imidazopyridine S1-1 at col. 3, line 50): PNG media_image5.png 930 774 media_image5.png Greyscale . Thus the claimed species would have been considered obvious. Applicants are to be aware of other species in this document as well which may render the claims obvious. Conclusion Claims 2-5 and 11-14 are rejected. Claim 9 is objected to. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN E MCDOWELL whose telephone number is (571)270-5755. The examiner can normally be reached on 8:30-6 MF. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN E MCDOWELL/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

May 14, 2022
Application Filed
Aug 19, 2025
Non-Final Rejection — §103, §112
Nov 06, 2025
Response Filed
Jan 28, 2026
Final Rejection — §103, §112
Apr 01, 2026
Request for Continued Examination
Apr 03, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599615
USE OF CAROTENOIDS IN THE TREATMENT OF SENESCENCE-RELATED DISEASES
2y 5m to grant Granted Apr 14, 2026
Patent 12604600
Organic Electroluminescent Element And Novel Iridium Complex
2y 5m to grant Granted Apr 14, 2026
Patent 12559494
NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE
2y 5m to grant Granted Feb 24, 2026
Patent 12552807
PCSK9 INHIBITORS AND METHODS OF USE THEREOF
2y 5m to grant Granted Feb 17, 2026
Patent 12545665
CRYSTAL FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+30.3%)
2y 4m
Median Time to Grant
Moderate
PTA Risk
Based on 1102 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month